Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ProMIS Neurosciences Inc. (PMN)

ProMIS Neurosciences shareholders approve 2025 plan increase at annual meeting

Neutral Impact 2 of 5 shareholder Written later

At its 2026 Annual Meeting on May 20, 2026, ProMIS Neurosciences shareholders approved an amendment adding 900,000 Common Shares to the 2025 Stock Option and Incentive Plan. Shareholders also elected all seven director nominees and ratified Baker Tilly US, LLP as the independent registered public accounting firm for fiscal 2026.

Key points

  • Plan amendment approved with 3,352,388 votes for, 774,193 against, 20,800 abstentions and 614,643 broker non-votes.
  • All seven nominees elected, including Neil Cashman, M.D. with 4,143,889 votes for and Eugene Williams with 4,108,919.
  • Baker Tilly US, LLP ratified with 4,657,634 votes for, 4,415 against and 99,975 abstentions.
  • Holders of 4,762,024 Common Shares, about 53.1% of 8,967,693 outstanding, were present or represented by proxy.

The filing

CompanyProMIS Neurosciences Inc. (PMN)
Form8-K, current report
Filed with the SECMay 20, 2026, 4:30 PM ET
Accession number0001104659-26-064545

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.